about
Multitargeted inhibitors in lung cancer: new clinical data.Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Angiogenesis and lung cancer: prognostic and therapeutic implications.Angiogenesis, metastasis, and lung cancer. An overview.Metastatic potential of human neoplasms.The role of growth factor signaling in malignancy.Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.New targets for the treatment of advanced non-small cell lung cancer.Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancerCurrent management of advanced non-small cell lung cancer: targeted therapy.Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models.Combined anti-proliferative and anti-angiogenic strategies for cancer.Targeted drug delivery strategies to treat lung metastasis.Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma.Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.Radiotherapy improves survival in unresected stage I-III bronchoalveolar carcinoma.Anti-angiogenic treatments in advanced NSCLC: back to the drawing board.Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.Preferences for disclosure of disease related information among thoracic cancer patients.EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy.Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.Weight loss and improvement of obesity-related illness in 500 U.S. patients following laparoscopic adjustable gastric banding procedure.Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.EGFR mutation testing practice in advanced non-small cell lung cancer.Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.Molecular targeted therapy for lung cancer.What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
P50
Q33440097-00A894D6-7307-4E9F-90E7-D79B6EDE0873Q34160907-6636B34B-E638-4437-9828-E92B9E07788CQ34417759-DFB75219-D45E-4F2B-9851-E707D5F8A107Q34988618-BD528574-5635-4F42-AC72-31C902114132Q35031551-B2EFAAAB-6A20-4042-B9AA-C10B10377517Q35076019-5D7F8E6F-1298-4BDE-98CB-870AB4556A8DQ35076393-DDA2706A-1198-4466-A54C-557115514634Q35110485-9213F595-2572-4401-92C4-BFBD8B04A292Q35896202-2C140D49-32C4-412B-9F56-9388DF00F59AQ35987286-2963209C-E0FE-48A4-911E-716A5CAB93C6Q36179387-A083F222-D494-4105-832A-29FB0E9BEF3CQ36267849-F864CAF4-B80C-4A77-876E-9D522D1F8EEFQ36715777-5ED1EA13-C98A-4DC2-9A8E-C978C2A464F7Q36750591-85C7EF54-E8C5-4DF1-9362-D11963A0F338Q36780671-BF600406-A36F-4CFB-A909-615688CCABD1Q37111832-F3464B03-8D7A-474A-AA74-D8C380602400Q37575499-A12BBE1D-F34B-45B1-AAC3-B76741CD949EQ37966339-C41819CA-1F1B-4075-B906-6A73F1FCDD70Q38942265-764EB4BD-C21F-4061-9E91-C119528C966CQ39208912-4670E201-8360-4D87-971A-9B63D00D3508Q39706169-6A226DBA-A670-4D33-B17E-00D784BBD4ABQ40026370-1E3D84BE-9FF5-4FE9-BDE0-1CEA177D9894Q40078206-63BEA444-A36C-4E21-A356-2988D2D6E200Q40169795-13DB3FEA-723C-4684-8E79-2F520E42EA28Q40205282-2676E4E6-F3DE-4625-B308-C82B1D44E379Q40257154-AE5B0561-6998-4CFC-A890-00E1BC338515Q40269505-E713A392-A835-4F1C-9326-631792A83855Q40559712-D9DE358B-F54F-4A82-BC05-158488DD8E3DQ40580619-EB336131-EF9D-4C2E-A28B-566407A6E338Q40610841-A74944BD-BBC4-4C19-B75C-B34B28FD2453Q41902466-7CC0F055-9BE9-4554-831D-6FA18480F2CFQ44246869-FE3F3895-7C0E-4803-9C1E-719AC14C7C48Q44900734-D9E1E340-66EB-45EE-A27A-A8DCCA2B1792Q45205111-EAF3ED8C-3C66-4170-8298-07FE7EFE97F1Q45243918-F8CF6994-8253-4EC2-AC1B-A62CA2A236ABQ45838956-47059366-0DBC-4FDA-9B64-87E628035957Q46780845-A80981CC-9471-494F-95DD-6B4C0B797042Q46787079-840065F6-2DE0-4828-8171-64175CCE1EC1Q46968796-5559FA09-56D9-4BB2-9DFA-9BB4628A342EQ47252774-02ED90DB-D8A3-4A15-986C-D48B6EFCA4C0
P50
description
researcher
@en
name
Amir Onn
@en
type
label
Amir Onn
@en
prefLabel
Amir Onn
@en
P31
P496
0000-0002-6602-0405